Mostrando 10 resultados de: 12
Filtros aplicados
Publisher
Clinical Pharmacology and Therapeutics(2)
European Journal of Clinical Pharmacology(2)
Acta Psychiatrica Scandinavica(1)
Anales de Medicina Interna(1)
European Journal of Cancer and Clinical Oncology(1)
Área temáticas
Farmacología y terapéutica(8)
Fisiología humana(3)
Medicina y salud(2)
Bioquímica(1)
Genética y evolución(1)
Origen
scopus(12)
Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis
ArticleAbstract: From a sample of 149 unrelated Spaniards, individuals were phenotyped for their ability to hydroxylaPalabras claves:Autores:Adrián LLerena, Avram M., Benitez Rodriguez J., Cobaleda J., Gibbons R., Henthorn T., Krejcie T., Martinez C.Fuentes:scopusDEBRISOQUINE HYDROXYLATION PHENOTYPES IN HEALTHY VOLUNTEERS
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J.Fuentes:scopusDebrisoquin oxidation polymorphism in a Spanish population
ArticleAbstract: The capacity for debrisoquin metabolism was determined in 377 healthy Spanish volunteers by measurinPalabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J.Fuentes:scopusDebrisoquine oxidation in schizophrenic patients treated with neuroleptics
ArticleAbstract:Palabras claves:debrisoquine, Neuroleptics, OXIDATION, SchizophreniaAutores:Adrián LLerena, Benitez Rodriguez J., Buemi A.L., Caputi A.P., Cobaleda J., García M.A., Piña B., Spina E.Fuentes:scopusDebrisoquine oxidation phenotype in psychiatric patients.
ArticleAbstract:Palabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., García M.A., Martínez C., Piñas B.Fuentes:scopusAcetylator polymorphism in Parkinson's disease
ArticleAbstract: Acetylator phenotype has been determined using sulphamethazine in 100 patients with Parkinson's disePalabras claves:acetylator phenotype, debrisoquine oxidation, drug polymorphism, Parkinsonism, sulphamethazineAutores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., Fernandez-Gundin M.J., Jimenez F.J., Ladero J.M., Martinez C., Muñoz J.J.Fuentes:scopusFrequency of S-mephenytoin hydroxylation deficiency in 373 spanish subjects compared to other Caucasian populations
ArticleAbstract: We have investigated the prevalence of poor metabolisers (PM) of S-mephenytoin in 373 unrelated, heaPalabras claves:caucasian, drug metabolism, Mephenytoin, pharmacogenetics, Phenotype, polymorphismAutores:Adrián LLerena, Benitez Rodriguez J., Bertilsson L., Carrillo J.A., Reviriego J., Valdivielso M.J.Fuentes:scopusOxidative polymorphism of debrisoquine in Parkinson's disease
ArticleAbstract: Oxidative phenotype and metabolic ratio (MR) of debrisoquine (DBQ) have been determined in 87 patienPalabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., Jimenez-Jimenez F.J., Ladero J.M., Martínez C., Muñoz J.J., Puerto A.M., Valdivielso M.J.Fuentes:scopusRelationship between personality and debrisoquine hydroxylation capacity: Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6
ArticleAbstract: We administered the Karolinska Scales of Personality to 225 healthy subjects in Spain selected fromPalabras claves:debrisoquine, personality, pharmacogeneticsAutores:Adrián LLerena, Benitez Rodriguez J., Bertilsson L., Cobaleda J., Edman G., Schalling D.Fuentes:scopusPolimorfismo acetilador en el cancer de pulm6n
ArticleAbstract: The acetylation phenotype was determined, by means of sulfamethazine measurement, in 87 patien ts (8Palabras claves:Acetylator, lung cancer, polymorphism, SulfamethazineAutores:Adrián LLerena, Benitez Rodriguez J., Cobaleda Polo J., Fernandez-Gundin M.J., Jara Sanchez C., Laredo Quesada J.M., Munoz Gonzalez J.J., Perez-Manga G., Vargas E.Fuentes:scopus